Molecular Profile | SMO S387N |
Therapy | Arsenic trioxide + Posaconazole |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | sensitive |
Create By | tyin |
Update By | tyin |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References | SMO S387N | Advanced Solid Tumor | sensitive | Arsenic trioxide + Posaconazole | Preclinical | Actionable | In a preclinical study, combination of Posaconazole and Trisenox (Arsenic trioxide) demonstrated enhanced inhibition of Hedghog signaling in mouse fibroblasts over expressing murine SMO S391N (corresponding to human SMO S387N) in culture (PMID: 26823493). | 26823493 |
---|
PubMed Id | Reference Title | Details |
---|---|---|
(26823493) | Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma. | Full reference... |